This is definitely a great news. Imagine that we can ease our minds by just having our blood work done... On a second thought after reading the report....especially after this paragraph: "The test involves monitoring the concentration of a panel of proteins in blood serum followed by a discriminant biostatistical analysis of the proteins ("biomarkers"), to distinguish between subjects with ALS and those with other neurological disorders (ALS-like) having clinical symptoms resembling them. " I doubt that the insurance company would like to cover it, because this test cannot become a diagnostic test (meaning test that makes a definite clear cut on whether you have or do not have a certain disease).Biostatistical analysis are generally not considered as a test of exclusion, it only gives you a numeric number of possibility/chances of how likely you have or don't have a disease. An example would be the test that we do for pregnant women to screen for possible fetal down-syndromes. I imagine that if the power of this ALS biostatistical analysis can be on par of the down-syndrome test, it will become a standard test. Before then, we will need more samples (600 patients are far from enough) to make the ALS test statistically powerful enough.